Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, announced the appointment of Dennis Dean, Ph.D., as ...

Eisai Co., Ltd.  and Biogen Inc. announced that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia ...

Veloxity Labs, a bioanalytical CRO built for programs that need speed with purpose, announced the acquisition of the ZenoTOF 8600 system from SCIEX, a global leader in life science analytical technologies. Veloxity is the first bioanalytical CRO in the United States to acquire this new accurate ...

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®. The new syringe is ergonomically engineered to elevate the treatment experience, offering greater precision, ...

Servier announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) glioma following surgical intervention and for whom chemoradiotherapy can be delayed were published in The ...

InterVene, Inc., a privately held medical device company pioneering interventional devices for venous occlusions, announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Recana® Thrombectomy Catheter System for treating venous in-stent restenosis and native ...